Since the development of tyrosine kinase inhibitors (TKIs), which inhibit the disease-causing BCR::ABL1 kinase and prevent downstream target phosphorylation, CML can be effectively treated (Druker et al., 1996). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.